Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Tavolixizumab Humanized Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA5-58737
应用
建议稀释比
已发表文章
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG1
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
偶联物
形式
Lyophilized
浓度
1 mg/mL
纯化类型
Protein A
保存液
25mM histidine, pH 6.2, with 0.01% Tween 80, 8% sucrose
内含物
no preservative
保存条件
-20°C, Avoid Freeze/Thaw Cycles
运输条件
Ambient (domestic); Dry ice (international)
RRID
产品详细信息
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
靶标信息
Tavolixizumab, also known as Tyenne® (tocilizumab-aazg), is a biosimilar to Actemra® (tocilizumab), an Interleukin-6 (IL-6) receptor antagonist. Tavolixizumab targets the IL-6 receptor, thereby inhibiting the IL-6 signaling pathway, which plays a crucial role in the inflammatory response associated with autoimmune diseases such as rheumatoid arthritis and systemic juvenile idiopathic arthritis. The biosimilar is available in various formulations, including prefilled syringes, pen injectors, and vials for subcutaneous and intravenous administration, providing versatile treatment options. Tavolixizumab has demonstrated efficacy and safety comparable to the reference product, with serious infections being one of the noted adverse effects. Synonyms for Tavolixizumab include tocilizumab-aazg and Tyenne.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
